[2] Wharton, Sean et al. “Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.” The New England journal of medicine vol. 389,10 (2023): 877-888. doi:10.1056/NEJMoa2302392 [3] Wilding, John P H et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesi...
（图片来源：《Triple–Hormone-Receptor Agonist Retatrutide for Obesity— A Phase 2 Trial》）在主要临床终点上，24周时，体重百分比方面，1 mg Retatrutide组为-7.2%，4 mg组为-12.9%，8mg组为-17.3%，而12 mg的组达到了-17.5%，安慰剂组为-1.6%。此外，次要临床终点48周的体重变化上，12mg组的...
下一篇，也就是GLP-1系列专题的最终章，我们将会继续分析DP工段将会涉及到的工艺以及相应的设备，敬请期待。参考文献 [1] 《多肽药物制备工艺研究进展》[2] 《Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP》[3] 《Kilogram-Scale GMP Manu...
GLP-1 agonist medications work bymimickingthis hormone. In medication terms, anagonistis amanufacturedsubstance that attaches to a cell receptor and causes the same action as the naturally occurring substance. In other words, GLP-1 medications bind to GLP receptors to trigger the effects (or roles...
[12] Noyan-Ashraf, M.H., Momen, M.A., Ban, K., Sadi, A.M., Zhou, Y.Q., Riazi, A.M., et al. 2009. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocar...
[2] Wharton, Sean et al. “Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.” The New England journal of medicine vol. 389,10 (2023): 877-888. doi:10.1056/NEJMoa2302392 [3] Wilding, John P H et al. “Onc...
me/src/EventPilot/php/express/web/page.php?page=IntHtml&project=ADA23&id=789.3. Zhao J, et al.LBA 66Efficacy and safety of HRS9531, a novel dual GLP-1/GIP receptor agonist, in patients with type 2 diabetes mellitus (T2DM): a phase 2 trial. Presented at EASD annual meeting.
资料1、LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept 资料2、The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetesl. 资料3、Targeting th...
1. 诺和诺德一季度报、司美格鲁肽各剂型说明书(EMA) 2. 中信证券、兴业证券、国金证券、诺和诺德官网等。 3. A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of 4. Type 2 Diabetes Mellitus. 5. 超级重磅!全球口服版GLP-1降糖药Rybelsus(semaglutide片)获美国FDA...
GLP-1（胰高血糖素样肽-1，glucagon-like peptide-1）于1987年被发现，是血糖稳态调节的重要靶点；而GLP-1RA（胰高血糖素样肽-1受体激动剂，glucagon-like peptide-1 receptor agonist, GLP-1RA）则被研发用于改善2型糖尿病的一些关键性病理生理缺陷，并具有减少心血管死亡、改善动脉粥样硬化、减轻体质量、降低...